Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DO-2 |
| Synonyms | |
| Therapy Description |
DO-2 is a selective MET inhibitor, which potentially induces cell death in tumor cells overexpressing MET (PMID: 38211518, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DO-2 | DO2|DO 2 | MET Inhibitor 59 | DO-2 is a selective MET inhibitor, which potentially induces cell death in tumor cells overexpressing MET (PMID: 38211518, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05752552 | Phase I | DO-2 | Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours | Active, not recruiting | NLD | FRA | BEL | 0 |